Loading...
Loading...
Evogene Ltd.
Evogene Ltd.. Spoken Alpha tracks EVGN's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks EVGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 4 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for EVGN.
curl https://api.spokenalpha.com/v1/companies/EVGN| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.20 | $1.95 | +13.0% | -1.8% | -4.7% |
| Q4 FY2026 | $2.21 | $2.05 | +7.7% | -7.3% | -5.6% |
| Q3 FY2026 | $2.40 | $2.07 | +15.8% | +3.1% | +0.5% |
| Q2 FY2026 | $1.99 | $1.96 | +1.4% | +4.3% | +5.3% |
| Q1 FY2025 | $2.07 | $1.95 | +6.3% | +2.2% | -0.6% |
| Q4 FY2025 | $2.33 | $2.06 | +13.3% | -2.3% | -2.2% |
| Q3 FY2025 | $2.42 | $2.10 | +15.4% | +0.7% | -1.6% |
| Q2 FY2025 | $2.10 | $1.97 | +6.6% | -1.1% | -3.9% |
| Q1 FY2024 | $2.43 | $2.11 | +15.3% | -3.3% | -2.4% |
| Q4 FY2024 | $2.36 | $2.20 | +7.2% | -1.0% | -1.7% |